The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study
A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
Hidradenitis suppurativa (HS) has an impact on patients' quality of life. Treatment of HS is generally unsatisfactory, thus new treatments are needed. ⋯ A significant reduction in HS severity was gained after 6 weeks. No long-term curative effect was uniformly seen.